Islatravir

A once-daily pill combining doravirine and islatravir maintained viral suppression for 48 weeks in Phase III trials, showing promise for HIV treatment without previous safety concerns. Merck plans to submit detailed data to the FDA for approval.

Merck announced positive phase 3 trial results for doravirine/islatravir, a once-daily, oral, two-drug regimen for HIV-1, showing non-inferiority to current therapies. The company plans to present findings and file with regulators, continuing its commitment to advancing HIV treatment options.

Merck announced positive Phase 3 results for doravirine/islatravir in HIV-1 trials, showing non-inferiority to current therapies and consistent safety.

Gilead Sciences, Inc. (GILD) shares gained 15.4% in a year, outperforming the sector but lagging the S&P 500. New drug approvals, pipeline progress, and strong quarterly results boosted investor sentiment. GILD raised its annual guidance, driven by Veklury sales. Its HIV portfolio, led by Biktarvy, continues to grow, with lenacapavir showing 100% efficacy for HIV prevention. Seladelpar's approval for primary biliary cholangitis strengthens GILD's liver disease portfolio. Despite setbacks in oncology, Trodelvy received Breakthrough Therapy Designation for small cell lung cancer. GILD's strong fundamentals and dividend yield make it a good long-term investment.

Merck & Co.'s islatravir, combined with doravirine, met primary efficacy goals in phase 3 trials for HIV-1 treatment, showing non-inferiority to existing therapies but not superiority in a Biktarvy comparison. Merck plans to advance islatravir combinations for HIV treatment, with detailed findings to be presented and submitted to regulators.

Merck announced positive Phase 3 trial results for DOR/ISL, a once-daily, oral, two-drug regimen for virologically suppressed HIV-1 adults, demonstrating non-inferiority to current therapies. Safety profiles were comparable, and Merck plans to present findings and file with regulators.

Merck & Co Inc. reported Phase 3 trial results for islatravir combined with doravirine in treating HIV-1. Trials met non-inferiority but not superiority criteria. Safety profiles were comparable. Data will be submitted to regulators. Ongoing studies include treatment-naive HIV patients. Islatravir is under evaluation in various HIV-1 treatment studies.

Merck & Co Inc announced topline results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) for HIV-1, showing non-inferiority to existing treatments. The trials met primary safety objectives, with detailed findings to be presented later. DOR/ISL is under evaluation in additional Phase 3 trials for HIV treatment.

Adnexus Biotechnologies Inc. appoints Dr. Hiroshi Ohrui, a renowned expert in medicinal chemistry and HIV drug development, to its Scientific Advisory Board. Dr. Ohrui's work on Islatravir, a potent anti-HIV drug, aligns with Adnexus's mission to innovate HIV treatments. The company also plans a strategic investment with 1606 Corp to enhance drug discovery capabilities.

Gilead Sciences and Merck's Phase 2 trial of a once-weekly oral HIV treatment, islatravir and lenacapavir, showed 94.2% viral suppression after 48 weeks, with no detectable viral loads. The regimen is set for Phase 3 trials, with a favorable safety profile and strategic collaboration between Gilead and Merck.